Vertex Pharmaceuticals (NASDAQ:VRTX) is gearing up to announce its quarterly earnings on Monday, 2025-08-04. Here’s a quick overview of what investors should know before the release.
Analysts are estimating that Vertex Pharmaceuticals will report an earnings per share (EPS) of $4.04.
The announcement from Vertex Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It’s worth noting for new investors that guidance can be a key determinant of stock price movements.
Historical Earnings Performance
Last quarter the company missed EPS by $0.23, which was followed by a 10.03% drop in the share price the next day.
Here’s a look at Vertex Pharmaceuticals’s past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 4.29 | 4.02 | 4.14 | 4.14 |
| EPS Actual | 4.06 | 3.98 | 4.38 | -12.83 |
| Price Change % | -10.0% | -3.0% | 6.0% | -2.0% |
Tracking Vertex Pharmaceuticals’s Stock Performance
Shares of Vertex Pharmaceuticals were trading at $456.87 as of July 31. Over the last 52-week period, shares are down 3.27%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
Analyst Observations about Vertex Pharmaceuticals
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vertex Pharmaceuticals.
With 10 analyst ratings, Vertex Pharmaceuticals has a consensus rating of Neutral. The average one-year price target is $482.9, indicating a potential 5.7% upside.